Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - Barclays (LON:BARC) has reduced its price target on Bruker (NASDAQ:BRKR) to $43.00 from $46.00 while maintaining an Overweight rating on the scientific instruments manufacturer. The stock currently trades at $35.1, down 13.5% over the past week, with InvestingPro data showing a relatively high P/E ratio of 66.3.
The price target adjustment follows Bruker’s second-quarter results, which revealed soft order numbers that had been anticipated by analysts.
Barclays noted that the primary investor concern centered around what the company’s guidance implied for the second half of the year, particularly given the steep ramp-up expected in the fourth quarter.
The research firm indicated that in the current uncertain macroeconomic environment, investors have "little appetite" for an outlook heavily weighted toward year-end performance, which will likely keep short-term sentiment on Bruker bearish.
Despite the near-term caution, Barclays suggested that longer-term investors may find opportunities to build positions in Bruker stock to potentially benefit from future earnings inflection and multiple re-rating once macroeconomic conditions stabilize.
In other recent news, Bruker Corporation announced its financial results for the second quarter of 2025, which did not meet analysts’ expectations. The company reported earnings per share (EPS) of $0.32, which was below the anticipated $0.42, representing a shortfall of 23.81%. Additionally, Bruker’s revenue was $797.4 million, slightly under the forecasted $812.81 million, indicating a 1.9% miss in revenue targets. These results were a surprise to investors and analysts alike, reflecting a challenging quarter for the company. The earnings miss has caught the attention of financial analysts, with some firms possibly reconsidering their evaluations of Bruker’s stock. Investors are closely monitoring these developments to assess their impact on future performance. These recent updates underscore the importance of keeping abreast of company earnings and analyst evaluations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.